

DOCKET NO.: ALLE0005-100
(17376 BOT)

PATENT

In the Claims:

Please cancel claim 8, without prejudice.

Please amends claims 1-4, 6 and 7 as follows:

Claim 1 (Currently amended). A modified ~~neurotoxin~~ botulinum toxin comprising at least one phosphorylation site added to the toxin as a secondary modification site, a ~~neurotoxin including a structural modification, wherein the structural modification is effective to alter the biological persistence of the modified neurotoxin relative to an identical neurotoxin without the structural modification, and wherein the modified~~ neurotoxin botulinum toxin is structurally different from a naturally occurring botulinum toxin neurotoxin.

Claim 2 (Currently amended). A ~~The modified neurotoxin botulinum toxin comprising of claim 1, wherein the structural modification includes the presence of one or more~~ The modified neurotoxin botulinum toxin comprising secondary modification sites in addition to the ones that are already naturally present.

Claim 3 (Currently amended). The modified ~~neurotoxin~~ botulinum toxin of claim 2, wherein the secondary modification site is a member selected from the group consisting of N-glycosylation, casein kinase II (CK-2) phosphorylation, N-terminal myristylation, protein kinase C (PKC) phosphorylation and tyrosine phosphorylation sites.

Claim 4 (Currently amended). ~~A~~ The modified neurotoxin botulinum toxin devoid of ~~claim 1, wherein the structural modification includes the absence of one or more~~ secondary modification sites that are found in an identical naturally existing neurotoxin.

Claim 5 (Original). The modified neurotoxin of claim 4, wherein the secondary modification site is a member selected from the group consisting of N-glycosylation,

**DOCKET NO.: ALLE0005-100
(17376 BOT)**

PATENT

casein kinase II (CK-2) phosphorylation, N-terminal myristylation, protein kinase C (PKC) phosphorylation and tyrosine phosphorylation sites.

Claim 6 (Currently amended). The modified neurotoxin of claim 2 ~~1~~, wherein the structural modification is effective to increase the biological persistence of the modified neurotoxin relative to an identical neurotoxin without the structural modification.

Claim 7 (Currently amended). The modified neurotoxin of claim 2 ~~1~~, wherein the structural modification is effective to decrease the biological persistence of the modified neurotoxin relative to an identical neurotoxin without the structural modification.

Claim 8 (Cancelled).

Claim 9 (New). A modified botulinum toxin comprising at least one secondary modification site added to the toxin, the secondary modification site is selected from a group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 and 46, wherein the modified botulinum toxin is structurally different from a naturally occurring neurotoxin.

Claim 10 (New). A modified botulinum toxin comprising at least one N-glycosylation site as a secondary modification site in addition to any N-glycosylation site that is naturally occurring on an unmodified neurotoxin wherein the modified botulinum toxin is structurally different from a naturally occurring neurotoxin.

Claim 11 (New). The modified neurotoxin toxin of claim 10, wherein the N-glycosylation site is SEQ ID NOs: 1, 2, 3, 4, 21, 22, 23, 24 or mixtures thereof.

**DOCKET NO.: ALLE0005-100
(17376 BOT)**

PATENT

Claim 12 (New). The modified neurotoxin toxin of claim 12, wherein the toxin is botulinum toxin type A.

Claim 13 (New). The modified neurotoxin toxin of claim 12, wherein the toxin is botulinum toxin type B.

Claim 14 (New). The modified neurotoxin toxin of claim 12, wherein the toxin is botulinum toxin type E.